Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation
4 affiliations
- 1Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital
- 2Department of Gastroenterology, The Second Affiliated Hospital of Shandong First Medical University
- 3Department of Emergency, Zhangjiagang First People’s Hospital
- 4Department of Rheumatology and Immunology, Dalian No.3 People’s Hospital
Abstract
Background: Excessive hepatocyte apoptosis triggered by toxic bile acids is the core pathological event of cholestasis, and the direct target of luteolin (Lut), the major bioactive constituent of Siphonostegia chinensis Benth., for this protective effect remains unclear. This study aims to elucidate how Lut suppresses hepatocyte apoptosis and ameliorates cholestatic liver injury.
Methods: A murine cholestasis model was induced by α-naphthylisothiocyanate (ANIT), and the hepatocyte apoptotic pathways were validated in glycochenodeoxycholic acid (GCDCA)-treated HepG2 cells. Liver tissue pathological changes were assessed via hematoxylin-eosin (HE) histological staining. Network pharmacology paired with supplementary RNA sequencing (RNA-seq) was used to screen candidate pathways contributing to Lut’s anti-cholestatic effects. Quantitative real-time PCR, Western blotting and Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) immunostaining were jointly utilized to assess apoptotic levels in liver parenchymal cells. Additionally, surface plasmon resonance (SPR) coupled with molecular docking simulations was adopted to clarify the direct binding profile of Lut.
Results: Lut treatment markedly ameliorated serum biochemical indices and liver histopathological lesions in ANIT-exposed mice. Meanwhile, oxidative stress was alleviated, bile acid transporters were restored, inflammatory cytokines declined, and hepatocyte apoptosis was suppressed. Network pharmacology combined with RNA-seq predicted that Lut alleviates cholestasis through the Phosphatidylinositol 3-kinase/Protein Kinase B (PI3K/AKT)-mediated anti-apoptotic pathway. This hypothesis was further supported by TUNEL, Western blotting, and qRT-PCR analyses, which indicated that Lut could activate the PI3K/AKT, and then suppress hepatocyte apoptosis in cholestasis. SPR analysis revealed a concentration-dependent direct interaction between Lut and PI3K with a kinetic KD of 9.036 × 10 ⁻⁵ M, and molecular docking revealed a plausible binding mode within the kinase domain. Additionally, the anti-apoptotic effect of Lut was largely abolished when PI3K was inhibited by LY294002 in vitro .
Conclusion: This study is the first to confirm that Lut directly targets PI3K to initiate the PI3K/AKT signaling cascade, and thereby suppresses bile acid-induced hepatocyte apoptosis. These findings refine the mechanistic understanding of Lut’s hepatoprotective action from general antioxidant activity to target-specific anti-apoptotic signaling, and provide a molecular explanation for the traditional use of S. chinensis Benth. for the treatment of damp-heat jaundice.
Related
- MOTS-c attenuates placental vascular endothelial cell apoptosis in intrahepatic cholestasis of pregnancy by inhibiting K33-linked deubiquitination of BACH1
- Dichloroacetate attenuates experimental acute liver injury and reduces hepatocyte apoptosis
- Fisetin Induces Apoptosis and Inhibits Migration of Melanoma Cells by Suppressing Glycolytic Metabolism via PKM2 Inhibition.
- Pharmacological TLR4 Activation Promotes Hepatocyte Proliferation and Liver Repair Through Coordinated IL-6 and TCDCA Signaling.
- The NF-κB-TNFAIP3 axis attenuates MASLD via activation of hepatocyte autophagy.
BibTeX
@article{zhao2026luteolin,
title = {{Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation}},
author = {Xingliang Zhao and Yingchong Xu and Hongyan Liang and Peixu Ji and Siyao Li and Sipu Wang and Xiaopei Guo and Jie Zhang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1930755},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1930755/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation
AU - Xingliang Zhao
AU - Yingchong Xu
AU - Hongyan Liang
AU - Peixu Ji
AU - Siyao Li
AU - Sipu Wang
AU - Xiaopei Guo
AU - Jie Zhang
PY - 2026
DA - 2026/10/07
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1930755
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1930755/full
AB - Background: Excessive hepatocyte apoptosis triggered by toxic bile acids is the core pathological event of cholestasis, and the direct target of luteolin (Lut), the major bioactive constituent of Siphonostegia chinensis Benth., for this protective effect remains unclear. This study aims to elucidate how Lut suppresses hepatocyte apoptosis and ameliorates cholestatic liver injury. Methods: A murine cholestasis model was induced by α-naphthylisothiocyanate (ANIT), and the hepatocyte apoptotic pathways were validated in glycochenodeoxycholic acid (GCDCA)-treated HepG2 cells. Liver tissue pathological changes were assessed via hematoxylin-eosin (HE) histological staining. Network pharmacology paired with supplementary RNA sequencing (RNA-seq) was used to screen candidate pathways contributing to Lut’s anti-cholestatic effects. Quantitative real-time PCR, Western blotting and Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) immunostaining were jointly utilized to assess apoptotic levels in liver parenchymal cells. Additionally, surface plasmon resonance (SPR) coupled with molecular docking simulations was adopted to clarify the direct binding profile of Lut. Results: Lut treatment markedly ameliorated serum biochemical indices and liver histopathological lesions in ANIT-exposed mice. Meanwhile, oxidative stress was alleviated, bile acid transporters were restored, inflammatory cytokines declined, and hepatocyte apoptosis was suppressed. Network pharmacology combined with RNA-seq predicted that Lut alleviates cholestasis through the Phosphatidylinositol 3-kinase/Protein Kinase B (PI3K/AKT)-mediated anti-apoptotic pathway. This hypothesis was further supported by TUNEL, Western blotting, and qRT-PCR analyses, which indicated that Lut could activate the PI3K/AKT, and then suppress hepatocyte apoptosis in cholestasis. SPR analysis revealed a concentration-dependent direct interaction between Lut and PI3K with a kinetic KD of 9.036 × 10 ⁻⁵ M, and molecular docking revealed a plausible binding mode within the kinase domain. Additionally, the anti-apoptotic effect of Lut was largely abolished when PI3K was inhibited by LY294002 in vitro . Conclusion: This study is the first to confirm that Lut directly targets PI3K to initiate the PI3K/AKT signaling cascade, and thereby suppresses bile acid-induced hepatocyte apoptosis. These findings refine the mechanistic understanding of Lut’s hepatoprotective action from general antioxidant activity to target-specific anti-apoptotic signaling, and provide a molecular explanation for the traditional use of S. chinensis Benth. for the treatment of damp-heat jaundice.
SN - 1663-9812
ER -